Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue treatment due to…Original Article
FDA Approves Ojjaara (momelotinib) for Myelofibrosis Patients with Anemia
